Obesity

Obesity & Metabolic Disorder

Obesity & Metabolic Disorder

Nearly every obesity drug on the market works the same way: suppress appetite, reduce calories, lose weight. The results are temporary. The biology fights back. Muscle is lost. Weight returns. Canary takes a fundamentally different approach. Rather than telling the brain to eat less, We reprogram fat cells themselves — converting inert fat-storing tissue into high-performance, calorie-burning beige adipocytes. The body doesn’t just lose weight. It learns to burn fat as its default state.
Canary’s dual-siRNA therapeutic delivered by subcutaneous injection directly into adipose tissue. Two precisely targeted gene-silencing molecules work in concert to remove the molecular brakes that keep white fat locked in storage mode — activating a self-sustaining cascade of thermogenic fat reprogramming, mitochondrial biogenesis, and systemic metabolic renewal. The result is energy expenditure from within — not appetite suppression from the brain.
Limitations of Current Obesity Treatments:
  • Up to 40% loss of lean muscle mass: unhealthy weight loss, compromising strength, metabolism, and long-term health outcomes
  • Focus on symptoms, not health: primarily suppressing appetite, failing to address the underlying metabolic issues or optimize body composition
  • Durability & adherence issues: Weekly injections and frequent side effects reduce adherence, while weight regain is common after stopping treatment

Canary Cure’s Solution:

  • Thermogenic, not catabolic: Our therapies increase the body’s resting energy expenditure by rebuilding its thermogenic infrastructure — driving fat loss while preserving and enhancing lean muscle mass. No approved drug does both simultaneously.
  • Adipocyte-selective with a better safety profile: Our LNP delivery platform targets subcutaneous adipose tissue with precision. No detectable drug reaches the brain or liver, creating a safety profile that sets a new standard for metabolic therapeutics. There is no mechanism for the neuropsychiatric side effects that have historically limited CB1R-targeting drugs, and none of the gastrointestinal toxicity associated with GLP-1 therapies.
  • Ultra-long duration — twice yearly: Our lead therapy, CCT-217, is designed for dosing every six months. Gene silencing creates a durable cellular phenotype change that persists long after the dose — eliminating the adherence burden of weekly or monthly injectables and the weight rebound that follows when conventional drugs are stopped.
  • Systemic benefit from a local target: Reprogrammed beige fat cells release powerful endocrine signals that improve liver fat, muscle quality, insulin sensitivity, and cardiovascular markers — a whole-body metabolic reset initiated by a single subcutaneous injection.

Canary’s Reprogram Platform

Canary’s Reprogram Platform represents a breakthrough in obesity treatment by transforming inactive white fat into metabolically active beige fat. Our flagship therapy, CCT-217, and developing pipeline assets target the root causes of metabolic dysfunction beyond appetite control.
Energy-storing human white adipocytes before treatment ​

Energy-storing human white adipocytes before treatment ​

Transformation towards fat burning human beige adipocyte

Transformation towards fat burning human beige adipocyte

CCT-217’s Remarkable Ability to Beige Human White Fat

This reprogramming of human fat cell to create metabolically active cells represents a significant breakthrough in translational adipose tissue research with profound implications for obesity therapeutics.
The first microscopic field reveals a dense population of human adipocytes which stores energy. The second picture reveals adipocytes that have undergone remarkable morphological transformation, following CCT-217 siRNA treatment into smaller, more numerous lipid droplets, in just 72 hours. The increased multilocularity (multiple small lipid droplets within cells) is characteristic of enhanced thermogenic capacity.
Beige adipose tissues predominantly functions to dissipate energy surplus, increasing resting energy expenditure and counteracting obesity. This is precisely the mechanism of action in Canary’s CCT-217 which treats obesity through the transformation of our white fat into metabolic active, fat burning beige fat.
Our Focus
  • Nearly every obesity drug on the market works the same way: Suppress appetite, reduce calories, lose weight. The results are temporary. The biology fights back. Muscle is lost. Weight returns. Canary takes a fundamentally different approach. Rather than telling the brain to eat less, we reprogram fat cells themselves — converting inert fat-storing tissue into high-performance, calorie-burning beige adipocytes. The body doesn’t just lose weight. It learns to burn fat as its default state.

    The thermogenic revolution in metabolic medicine begins in the adipose tissue, transforming it from storage mode to energy expenditure mode — and Canary has engineered the switch.

    Three Disease Areas. One Platform.
  • Obesity: Unlike conventional approaches, our therapies prioritize fat loss, preservation of lean body mass and body composition improvement. Our novel dual siRNA therapeutics target the energy expenditure systems - promoting the browning of white fat to increase metabolism and facilitate sustainable healthy weight loss. With the convenience of less frequent dosing and better safety profile, this dual gene silencing therapy offers a sustainable biological solution where current therapies only offer temporary suppression.
  • MASH (Metabolic Dysfunction-Associated Steatohepatitis): By activating the liver’s own fat-burning signals through the adipose endocrine system, our therapies address the underlying metabolic dysfunction driving fatty liver disease and inflammation — without targeting the liver directly.
  • Rare Metabolic Disease: In conditions where disordered energy metabolism drives pathology, Canary’s ability to re-establish healthy metabolic balance offers a pioneering therapeutic approach for patients with Prader-Willi Syndrome, Hypothalamic Obesity, Bardet-Biedl Syndrome, and Congenital Lipodystrophy. We are developing a dual RNA metabolic restoration platform that directly modulates the gene expression pathways driving these conditions, offering a fundamentally different approach from the symptomatic strategies that families and clinicians currently rely on.
Through thermogenic adipose reprogramming, Canary’s proprietary combinatorial therapies hold the potential to overcome the limitations of single-target approaches and achieve more effective and sustained weight loss while enhancing lean mass, and promoting metabolic stability.

Our goal is metabolic restoration and long term-health.
By addressing both energy expenditure and appetite control, Canary’s proprietary combinatorial therapy holds the potential to overcome the limitations of single-target approaches and achieve more effective and sustained weight loss.
Our goal is metabolic stability and long-term health.
Thermogenesis

Thermogenesis

Harnessing the Power of Thermogenesis to Promote Metabolic Health

Our bodies have a remarkable ability to regulate energy balance and maintain a healthy weight. One crucial process in this regulation is thermogenesis, the conversion of energy into heat, our body’s natural mechanism in regulating energy. We use advanced lipid nanoparticle (LNP) technology to deliver therapeutic molecules precisely to the tissues responsible for generating heat. By increasing thermogenesis (fat burning) and lipolysis (fat breakdown), we can increase energy expenditure and promote fat loss.
In activating specific pathways involved in thermogenesis, Canary’s patent pending therapy aims to boost the body's own ability to burn calories and utilize stored fat.
Batokines’ Signaling Power
CCT-217 uses a ”act locally, treat systemically" approach where the therapeutic agent remains localized at the injection site while the biological effects spread throughout the body through the signaling pathways of batokines - bioactive signaling molecules secreted by human beige adipocytes
Batokines affect multiple tissues:
  • Liver: Reducing steatosis & improving lipid metabolism
  • Visceral fat: Reducing accumulation in retroperitoneal, mesenteric, and gonadal depots
  • Muscle: Preserving and enhancing lean mass
  • Bone marrow: Reversing adiposity
Monogenic Obesity

Monogenic Obesity

Pioneering RNA Therapeutics for Severe Pediatric Obesity

Rare pediatric obesity is a catastrophic problem for children. Obesity caused by gene mutations, such as in Prader-Willi Syndrome (PWS), causes children to have an insatiable appetite and rapid weight gain. The early-onset obesity can cause cardiovascular and metabolic comorbidities and is associated with increased mortality.
PWS, a rare, complex genetic disorder requiring multi-disciplinary care currently has no cure. Our lead product, CCT-987 is designed to directly correct the peripheral adipose biology. By delivering a payload of CB1R siRNA and Leptin mRNA directly to subcutaneous adipose tissue. The dual RNA therapy achieves true metabolic restoration - driving profound improvements in the fat-to-muscle ratio and systemic metabolic parameters that far exceed the capabilities of centrally acting agents.
"While the field has made vital strides in managing the behavioral symptoms of PWS, the structural and metabolic deficits have remained largely out of reach. CCT-987 changes that paradigm. A treatment that promotes weight loss while actively enhancing lean mass isn't just an improvement—it's a fundamentally different therapeutic proposition.

For these patients, achieving metabolic restoration and reversing profound muscle weakness could be absolutely life-changing.”
- Dr. Jennifer Miller, MD
Renowned Clinician and KOL in Pediatric Endocrinology and PWS
Every child deserves the opportunity to thrive. By developing safe and effective RNA therapies for severe early-onset obesity, we strive to:

Empower Children

Help children achieve a healthy weight and improve their quality of life.

Support Families

Provide families with hope and a path towards better health for their children.

Advance Science

Drive innovation in RNA therapeutics and pave the way for new treatment options.

Pioneering RNA Therapy

We are revolutionizing healthcare by harnessing the power of cutting-edge RNA therapies to develop and deliver innovative treatments that addresses the root causes of diseases. We are committed to fostering a culture of scientific excellence and collaboration to create life-changing treatments that are safe, effective, and accessible to all.

Disclaimer: Canary Cure Therapeutics Inc’s website includes future planned care offerings, that are currently in development and are subject to regulatory approval before they are able to be commercialized

Quick Links

Useful Links

Quick Contact

  • 5063 N Service Road, Suite 100, Burlington, ON, Canada
  • info@canarycure.com
Copyright © 2026 Canary Cure Therapeutics Inc. All rights reserved.